Entrada Therapeutics
TRDA
120 hedge funds and large institutions have $343M invested in Entrada Therapeutics in 2026 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 47 increasing their positions, 32 reducing their positions, and 13 closing their positions.
54% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 13
47% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 32
28% more capital invested
Capital invested by funds: $269M → $343M (+$74.6M)
5% more funds holding
Funds holding: 114 → 120 (+6)
2.62% more ownership
Funds ownership: 68.47% → 71.09% (+2.6%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.42M |
| 2 |
LP
Longaeva Partners
Chicago,
Illinois
|
+$2.35M |
| 3 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$2.28M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.28M |
| 5 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$1.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
-$1.45M |
| 2 |
AG
Algert Global
San Francisco,
California
|
-$1.32M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.14M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$1.01M |
| 5 |
Morgan Stanley
New York
|
-$964K |
TRDA Hedge Fund Activity: Q1 2026 in Review
120 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q1 2026, worth a combined $343M — up 28% from $269M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new TRDA positions and 13 closed out — a net gain of 7 holders — while 47 added to existing stakes and 32 trimmed.
The largest buyer was BlackRock, adding an estimated $2.42M. The largest seller was Royce & Associates, cutting an estimated $1.45M.
- 120 institutional investors held Entrada Therapeutics (TRDA) as of Q1 2026, up from 114 in Q4 2025.
- Funds reported $343M of Entrada Therapeutics stock for Q1 2026, up 28% quarter-over-quarter.
- 20 funds opened new Entrada Therapeutics positions in Q1 2026 and 13 closed out, a net change of +7 holders.
- The largest Entrada Therapeutics buyer in Q1 2026 was BlackRock, an estimated $2.42M added.
- The largest Entrada Therapeutics seller in Q1 2026 was Royce & Associates, an estimated $1.45M sold.
Based on aggregated 13F filings for Q1 2026.